# Aziende Chimiche Riunite Angelini trials: 40

ClinicalTrials.gov lists 40 trials with Aziende Chimiche Riunite Angelini Francesco S.p.A as lead sponsor, 1 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Aziende Chimiche Riunite Angelini Francesco S.p.A: 40 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/aziende-chimiche-riunite-angelini-francesco-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 30, 2026 | NCT07377682 | Real-world Clinical Response to Trazodone in Italy, Poland, and Romania | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Recruiting | Depression - Major Depressive Disorder, Cognition Disorders in Old Age | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377682) |
| September 30, 2025 | NCT07199543 | Palatability Study of Five Formulations of Benzydamine HCl Lozenges | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 1 | Completed | Healthy Volunteers, Palatability, To Test the Palatability of a New Flavour and Four Commercially Available Flavours | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199543) |
| April 10, 2025 | NCT06922175 | REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Epilepsy With Uncontrolled Focal-onset Seizures | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06922175) |
| January 14, 2025 | NCT06773767 | Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state. | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 1 | Completed | Bioavailability Heathy Volunteers, Bioavailability Study, Bioequivalance | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06773767) |
| December 4, 2024 | NCT06716801 | Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Focal Epilepsy With and Without Secondary Generalization | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716801) |
| October 21, 2024 | NCT06650631 | The Effectiveness of Heat Treatment on Knee Pain in Patients With Osteoarthritis - an International, Multicenter Clinical Investigation | Aziende Chimiche Riunite Angelini Francesco S.p.A | Not applicable | Completed | Pain Management, Osteoarthritis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06650631) |
| July 30, 2024 | NCT06527885 | Lurasidone Non-Interventional Study in Schizophrenia Patients | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Schizophrenia | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06527885) |
| April 10, 2024 | NCT06358586 | New Paediatric Formulation of Tachipirina® | Aziende Chimiche Riunite Angelini Francesco S.p.A | Not applicable | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06358586) |
| November 1, 2023 | NCT06111118 | The Effectiveness of Sustained Heat Treatment on Delayed-Onset Muscle Soreness (DOMS) | Aziende Chimiche Riunite Angelini Francesco S.p.A | Not applicable | Completed | Delayed-Onset Muscle Soreness (DOMS) | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06111118) |
| May 19, 2023 | NCT05867160 | Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Epilepsy | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05867160) |
| May 16, 2023 | NCT05859854 | Cenobamate in Adults With Focal-Onset Seizures | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Epilepsy, Focal-Onset Seizure, Neurological Disorder | 936 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05859854) |
| February 28, 2023 | NCT05747001 | This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program... | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Focal Onset Seizure, Epilepsy | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05747001) |
| February 3, 2022 | NCT05222724 | Efficacy of the Combination of Ibuprofen and Paracetamol in Acute Non-specific Low Back Pain | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | Completed | Low Back Pain | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05222724) |
| January 24, 2022 | NCT05204667 | Different Dosage Regimens of Methocarbamol/Paracetamol in Acute Non-specific Low Back Pain. MioPain Study | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | Terminated | Low Back Pain | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05204667) |
| November 29, 2021 | NCT05136521 | Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release... | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05136521) |
| September 24, 2021 | NCT05055726 | Benzydamine Oromucosal Solution in Oral Mucositis (BOOM) | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | Completed | Radiation-Induced Mucositis, Head and Neck Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05055726) |
| July 13, 2021 | NCT04959799 | Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Diabetes, Infection | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04959799) |
| June 28, 2021 | NCT04941976 | Benzydamine in Sore Throat Pain Relief (BePaiR Study) | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 4 | Completed | Acute Sore Throat | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04941976) |
| December 21, 2020 | NCT04678076 | Bioequivalence of Ketoprofen Oral Gel vs Ketoprofen Lysine Salt as Granules for Oral Solution | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04678076) |
| December 17, 2020 | NCT04670601 | Bioequivalence of Flurbiprofen Lozenge vs Strepfen | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04670601) |
| July 13, 2020 | NCT04468490 | Treatment of Breakthrough Cancer Pain According to European Guidelines | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Terminated | Breakthrough Cancer Pain | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04468490) |
| March 18, 2020 | NCT04312503 | Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Schizophrenia | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04312503) |
| March 6, 2020 | NCT04298463 | Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Acute Bacterial Skin and Skin Structure Infection | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04298463) |
| March 5, 2020 | NCT04295941 | Long-term Study With Trazodone Once-a-Day | Aziende Chimiche Riunite Angelini Francesco S.p.A | Observational | Completed | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04295941) |
| November 21, 2018 | NCT03749642 | Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 2 | Completed | Painful Diabetic Neuropathy | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03749642) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 6 |
| Phase 3 | 1 |
| Phase 4 | 5 |
| Not applicable | 3 |
| Observational | 12 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Terminated | 3 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 5 |
| Seizures | 4 |
| Depressive Disorder, Major | 3 |
| Diabetic Neuropathies | 2 |
| Neuralgia | 2 |
| Schizophrenia | 2 |
| Low Back Pain | 2 |
| Agnosia | 1 |
| Osteoarthritis | 1 |
| Pain | 1 |
| Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Stomatitis | 1 |
| Bipolar Disorder | 1 |
| Tremor | 1 |
| Prostatitis | 1 |
| Metabolic Syndrome | 1 |
| Cellulitis | 1 |
| Coronary Restenosis | 1 |
| Nervous System Diseases | 1 |
| Hyperthermia | 1 |
| Motor Activity | 1 |
| Depression | 1 |
| Leukemia, Hairy Cell | 1 |
| Diabetes Mellitus | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Packing services in the United States](https://specstream.ai/data/businesses/packing-services/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Georgian restaurants in the United States](https://specstream.ai/data/businesses/georgian-restaurants/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Asian fusion restaurants in the United States](https://specstream.ai/data/businesses/asian-fusion-restaurants/united-states)
